Galecto Biotech
7 known investors
Damora Therapeutics is a biotechnology company developing subcutaneous biologics as targeted, disease-modifying treatments for patients with mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis. Its lead asset, DMR-001, is an investigational monoclonal antibody targeting mutCALR, with a first regulatory submission planned for mid-2026.
BiotechMedical Devices
Founders & leadership
JJ
Jennifer JarrettChief Executive Officer & Board Director
SS
Sherwin SattarzadehChief Operating Officer
BH
Becker HewesChief Medical Officer
GW
Garrett WinslowGeneral Counsel
JB
Jim BakerChief Corporate Affairs Officer
BB
Brian BurkavageSenior Vice President, Finance
Investors · 7
In the news
Frequently asked questions
- What does Galecto Biotech do?
- Damora Therapeutics is a biotechnology company developing subcutaneous biologics as targeted, disease-modifying treatments for patients with mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis. Its lead asset, DMR-001, is an investigational monoclonal antibody targeting mutCALR, with a first regulatory submission planned for mid-2026.
- Who are Galecto Biotech's investors?
- Galecto Biotech's investors include EIR Ventures, M Ventures, SEED Capital Denmark, Sunstone Capital, Ysios Capital, Maverick Ventures, OrbiMed.